2nd Rare Disease Collaboration

Start

Wed, 15 Jul 2015, 08:00

End

Thu, 16 Jul 2015, 05:00

WebSite

Venue:

With more than 6,000 rare diseases recognized by the NIH, the market for orphan and ultra-orphan indications represents a major growth area for pharma and biotech companies. But low patient numbers combined with the urgency of unmet medical needs can make standard clinical trial procedures unfeasible.

Exhibit

Symposia

Workshops

Organiser

Sponsor

General Info

ExL Pharma’s 2nd Rare Disease Collaboration Summit gives you the tools you need to build lasting partnerships with patient advocacy groups in order to construct more flexible and patient-centric clinical trial protocols and accelerate the regulatory approval of your orphan drug.

This event hosts the formation of working group relationships that harness the collective resources of industry and patient advocates, creating a working framework for shaping legislation and convincing regulators. Build best practice outputs that outlive the meeting!

Registration and Fees

Fees:

Standard Rate Price

Conference Only $2,095

Onsite Rate

Conference Only $2,195

Payment:

Make checks payable to ExL Events, Inc. (ExL Pharma) and write code C614 on your check. You may also use Visa, MasterCard, Discover or American Express. Payments must be received in full by the conference date. Any discount applied cannot be combined with any other offer‚ and must be paid in full at the time of order. Parties must be employed by the same organization and register simultaneously to realize group discount pricing options. Group discounts available to individuals must be registered simultaneously and employed by the same organization.**Please note, there will be an administrative charge of $300 to substitute, exchange and/or replace attendance badges with a colleague occurring within five business days of any ExL conference.**

Click here to register.

Topics

The Cost of Innovation — Productive Conversation Across All Rare Disease Medicine Stakeholders
Case Study: Catalyzed Development of Therapeutics for Rare Diseases with Public-Private Partnerships
Case Study: Alternative Models to Discovering and Developing Orphan Therapeutics Study
Case Study: Partner with Patient Advocacy Groups to Collaborate and Achieve Success Over Orphan Therapies Study
Case Study: Patient Development Enhancement Techniques for Friedreich’s Ataxia Research Alliance
A New Framework for Patient and Academic Collaboration in Rare Diseases

#RDD2015